氟唑帕利治疗卵巢上皮性癌患者的真实世界临床数据分析
本研究回顾性分析4620例接受氟唑帕利单药或联合治疗的卵巢癌患者基线特征,并前瞻性入组224例患者分析疗效与安全性。前瞻性队列中一线维持、铂敏感复发后维持、铂敏感复发后直接治疗、铂耐药复发后直接治疗的中位无进展生存分别为随访期内未达到、12.6个月、随访期内未达到、4.8个月。结论认为氟唑帕利疗效与同类药物基本一致,安全性良好。
要点
- 前瞻性队列205例有安全性记录者中,62.0%(127/205)出现治疗相关副反应,常见为贫血、血小板计数降低和白细胞计数降低。
- 21.0%(43/205)出现3级及以上治疗相关副反应,常见为贫血(8.3%,17/205)和血小板计数降低(8.3%,17/205)。
- 铂敏感复发后维持治疗者中位无进展生存为12.6个月,1年无进展生存率为55.0%。
核心结论
- 氟唑帕利在临床应用中的疗效与同类药物基本一致,安全性良好,为氟唑帕利在卵巢癌领域的治疗提供了新的临床证据。
研究设计与样本
- 回顾性分析4620例已接受氟唑帕利单药或联合治疗的卵巢癌患者的基线特征。
- 前瞻性入组224例有意愿接受氟唑帕利单药或联合治疗的卵巢癌患者,收集并分析基线资料、治疗效果及安全性数据。
主要发现
- 回顾性队列4620例中位年龄60岁,卵巢癌占89.8%(4149/4620),有明确记录者中浆液性癌占82.9%(3770/4546),FIGO Ⅲ~Ⅳ期占90.9%(1537/1691)。
- 前瞻性队列224例中位年龄57岁,卵巢癌占83.9%(188/224),有明确记录者中浆液性癌占91.9%(193/210),FIGO Ⅲ~Ⅳ期占79.9%(139/174)。
- 前瞻性队列中一线维持84例、铂敏感复发后维持92例、铂敏感复发后直接治疗23例、铂耐药复发后直接治疗19例,中位随访时间分别为8.5、8.7、7.9、6.7个月。
- 上述四组中位氟唑帕利治疗持续时间分别为6.7、4.8、3.1、1.9个月,中位无进展生存分别为随访期内未达到、12.6个月、随访期内未达到、4.8个月,1年无进展生存率分别为84.1%、55.0%、69.8%、45.5%,其余6例接受其他氟唑帕利治疗方案。
- 前瞻性队列205例有安全性记录者中,127例(62.0%,127/205)出现治疗相关副反应,常见为贫血(24.4%,50/205)、血小板计数降低(21.0%,43/205)和白细胞计数降低(19.5%,40/205);43例(21.0%,43/205)出现3级及以上治疗相关副反应,常见为贫血(8.3%,17/205)和血小板计数降低(8.3%,17/205)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the safety and effectiveness of fuzuloparib for the treatment of ovarian epithelial cancer patients in the real world setting. Methods: A retrospective analysis was conducted on the baseline data of 4 620 ovarian cancer patients who had received fuzuloparib monotherapy or combination therapy. Another 224 ovarian cancer patients who were willing to receive fuzuloparib monotherapy or combination therapy were prospectively enrolled, and their baseline characteristics, drug effectiveness, and safety data were analyzed. Results: (1) Among the 4 620 patients in the retrospective cohort, the median age of patients was 60 years; tumor types: 89.8% (4 149/4 620) had ovarian cancer. Among patients with clearly documented information, the vast majority had a histological type of serous carcinoma (82.9%, 3 770/4 546) and International Federation of Gynecology and Obstetrics (FIGO) staging of Ⅲ-Ⅳ (90.9%, 1 537/1 691). (2) Among the 224 patients in the prospective cohort, the median age of patients was 57 years; tumor types: 83.9% (188/224) had ovarian cancer. Among patients with clearly documented records, the predominant pathologic type was serous carcinoma (91.9%, 193/210), and FIGO stage was Ⅲ-Ⅳ in 79.9% (139/174). (3) Among the 224 prospective patients: 84 patients received first-line fluzoparib maintenance therapy, 92 patients received fluzoparib maintenance therapy after platinum-sensitive recurrence, 23 patients received direct fluzoparib treatment after platinum-sensitive recurrence, 19 patients received direct fluzoparib treatment after platinum-resistant recurrence. The median follow-up durations were 8.5, 8.7, 7.9, and 6.7 months, respectively. The median durations of fluzoparib treatment were 6.7, 4.8, 3.1, and 1.9 months, respectively. The median progression-free survival (PFS) times were not reached during follow-up, 12.6 months, not reached during follow-up, and 4.8 months, respectively. The 1-year PFS rates were 84.1%, 55.0%, 69.8%, and 45.5%, respectively. The remaining 6 patients received other fluzoparib regimens. (4) Among the 224 patients in the prospective dataset, 205 had safety data recorded. Of these, 127 patients (62.0%, 127/205) experienced treatment-related adverse events, with common events including anemia (24.4%, 50/205), thrombocytopenia (21.0%, 43/205), and leukopenia (19.5%, 40/205). Among the 205 patients, 43 (21.0%, 43/205) experienced grade 3 or higher treatment-related adverse events, with common events including anemia (8.3%, 17/205) and thrombocytopenia (8.3%, 17/205). Conclusions: The effectiveness of fuzuloparib in clinical application is generally consistent with other drugs in the same class, with good safety. This study provids new clinical evidence for the treatment of ovarian cancer with fuzuloparib. 目的: 根据真实世界临床数据评估氟唑帕利治疗卵巢上皮性癌(卵巢癌)的有效性和安全性。 方法: 回顾性分析4 620例已经接受氟唑帕利单药或联合治疗的卵巢癌患者的基线特征。另外,前瞻性入组224例有意愿接受氟唑帕利单药或联合治疗的卵巢癌患者,并对这部分患者的基线资料、氟唑帕利治疗效果及安全性数据进行收集和分析。 结果: (1)回顾性队列中,4 620例接受氟唑帕利单药或联合治疗患者的中位年龄为60岁;肿瘤类型:卵巢癌占比最高,为89.8%(4 149/4 620);在有明确记录的患者中,大多数患者的病理类型为浆液性癌(82.9%,3 770/4 546),国际妇产科联盟(FIGO)分期为Ⅲ~Ⅳ期(90.9%,1 537/1 691)。(2)前瞻性队列中,224例患者的中位年龄为57岁;肿瘤类型:83.9%(188/224)的患者为卵巢癌;在有明确记录的患者中,大多数患者的病理类型为浆液性癌(91.9%,193/210),FIGO分期为Ⅲ~Ⅳ期(79.9%,139/174)。(3)前瞻性队列的224例患者中,84例为氟唑帕利一线维持治疗、92例为铂敏感复发后氟唑帕利维持治疗、23例为铂敏感复发后氟唑帕利直接治疗、19例为铂耐药复发后氟唑帕利直接治疗,中位随访时间分别为8.5、8.7、7.9、6.7个月,中位氟唑帕利治疗持续时间分别为6.7、4.8、3.1、1.9个月,中位无进展生存(PFS)时间分别为随访期内未达到、12.6个月、随访期内未达到、4.8个月,1年PFS率分别为84.1%、55.0%、69.8%、45.5%;其余6例接受其他氟唑帕利治疗方案。(4)前瞻性队列的224例患者中,205例有安全性数据的记录,其中127例(62.0%,127/205)出现治疗相关的副反应,常见者为贫血(24.4%,50/205)、血小板计数降低(21.0%,43/205)和白细胞计数降低(19.5%,40/205);43例(21.0%,43/205)患者出现3级及以上治疗相关的副反应,常见者为贫血(8.3%,17/205)和血小板计数降低(8.3%,17/205)。 结论: 氟唑帕利在临床应用中的疗效与同类药物基本一致,安全性良好,为氟唑帕利在卵巢癌领域的治疗提供了新的临床证据。.
引用
- Weng DH, Jiang J, Yang YJ, et al. [Real world clinical data analysis of fuzuloparib for the treatment of ovarian epithelial cancer patients]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 40854744. doi:10.3760/cma.j.cn112141-20241119-00614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。